炎症性肠病患者中的家族性地中海热:一项来自epi-IIRN的全國性研究
基于覆盖以色列98%人口的epi-IIRN队列,纳入34375例炎症性肠病(IBD)患者与93602例匹配对照,比较家族性地中海热(FMF)患病率。IBD患者FMF患病率0.5%高于对照0.2%(OR=2.68,95%CI 2.2-3.3;P<0.001),克罗恩病(CD)高于溃疡性结肠炎(UC),多数病例FMF诊断先于IBD,UC合并FMF者进展至生物制剂治疗更快。
要点
- IBD患者FMF患病率0.5% vs 非IBD对照0.2%(OR=2.68,95%CI 2.2-3.3;P<0.001)。
- CD患者FMF患病率0.6% vs UC 0.3%(OR=2.1,95%CI 1.5-3.0,P<0.001)。
- 157例IBD合并FMF者中130例(83%)FMF诊断先于IBD诊断。
核心结论
- FMF在IBD患者中较一般人群更常见,尤其在CD中;多数病例FMF诊断先于IBD,且可能与UC更严重的病程相关。
研究设计与样本
- 利用epi-IIRN队列数据(覆盖以色列98%人口),比较IBD患者与非IBD对照的FMF调整患病率;IBD按经验证的算法确定,FMF按ICD-9编码及秋水仙碱购买记录确定。
- 共纳入34375例IBD患者(56%为CD,44%为UC)与93602例匹配对照。
主要发现
- IBD患者中157例(0.5%)患FMF,非IBD对照中160例(0.2%)患FMF(OR=2.68 [95%CI 2.2-3.3];P<0.001)。
- 儿童起病IBD的FMF患病率为30/5243(0.6%),成人起病IBD为127/29132(0.4%),无统计学显著性(OR=1.31 [0.88-1.96];P=0.2)。
- FMF在CD中患病率为114/19264(0.6%),高于UC的43/15111(0.3%)(OR=2.1 [1.5-3.0],P<0.001)。
- 157例中130例(83%)FMF诊断先于IBD诊断。
- UC合并FMF者诊断时疾病活动度更重,CD合并FMF者则无此关联;CD合并FMF与单纯CD的结局相当,而UC合并FMF者至生物制剂治疗的时间更短。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Inflammatory bowel diseases (IBD) and familial Mediterranean fever (FMF) are auto-inflammatory diseases with common clinical and biological features. We aimed to determine their association and characterize the natural history in patients with both diagnoses. METHODS: Utilizing data from the epi-IIRN cohort, which includes 98% of Israel's population, we calculated the adjusted prevalence of FMF among IBD patients vs non-IBD controls. Case ascertainment of IBD was determined according to validated algorithms and for FMF by ICD-9 codes and colchicine purchase. RESULTS: In total, 34 375 IBD patients (56% Crohn's disease [CD] and 44% ulcerative colitis [UC]) were compared with 93 602 matched controls. Among IBD patients, 157 (0.5%) had FMF compared with 160 (0.2%) of non-IBD controls (OR = 2.68 [95%CI 2.2-3.3]; P < 0.001). Pediatric-onset IBD had a higher prevalence of FMF compared with adult-onset IBD (30/5243 [0.6%] vs 127/29 132 [0.4%]), without statistical significance (OR = 1.31 [0.88-1.96]; P = 0.2). FMF was more prevalent in CD (114/19 264 [0.6%]) than UC (43/15 111 [0.3%]; OR = 2.1 [1.5-3.0], P < 0.001). FMF diagnosis preceded that of IBD in 130/157 cases (83%). FMF was associated with a more severe disease activity in UC patients at diagnosis, but not in CD patients. Outcomes were comparable between patients with CD+FMF vs CD alone; however, in patients with UC+FMF, time to biologic treatment was shorter. CONCLUSION: FMF is more prevalent in IBD patients than in the general population, particularly in CD. The diagnosis of FMF precedes the diagnosis of IBD in most cases, and may be associated with a more severe course in UC.
引用
- Kori M, Buchuk R, Goldzweig O, et al. Familial Mediterranean fever in patients with inflammatory bowel diseases: a nationwide study from the epi-IIRN. Rheumatology (Oxford). 2025. PMID: 38814796. doi:10.1093/rheumatology/keae303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。